Literature DB >> 24283232

RAS mutations in colorectal cancer.

Jean-Yves Douillard, Alan Rong, Roger Sidhu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24283232     DOI： 10.1056/NEJMc1312697

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  21 in total

1.  NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Authors:  Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2014-11       Impact factor: 11.908

2.  KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.

Authors:  Dominic Leiser; Michaela Medová; Kei Mikami; Lluís Nisa; Deborah Stroka; Andree Blaukat; Friedhelm Bladt; Daniel M Aebersold; Yitzhak Zimmer
Journal:  Mol Oncol       Date:  2015-04-14       Impact factor: 6.603

Review 3.  Primary and acquired resistance to biologic therapies in gastrointestinal cancers.

Authors:  Sam J Lubner; Nataliya V Uboha; Dustin A Deming
Journal:  J Gastrointest Oncol       Date:  2017-06

4.  β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models.

Authors:  Shanthi Ganesh; Xue Shui; Kevin P Craig; Martin L Koser; Girish R Chopda; Wendy A Cyr; Chengjung Lai; Henryk Dudek; Weimin Wang; Bob D Brown; Marc T Abrams
Journal:  Mol Cancer Ther       Date:  2017-12-27       Impact factor: 6.261

Review 5.  Optimizing biologic sequencing in metastatic colorectal cancer: first line and beyond.

Authors:  Z Jin; J M Hubbard
Journal:  Curr Oncol       Date:  2019-11-01       Impact factor: 3.677

6.  Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study.

Authors:  Feng Wen; Yu Yang; Pengfei Zhang; Jian Zhang; Jing Zhou; Ruilei Tang; Hongdou Chen; Hanrui Zheng; Ping Fu; Qiu Li
Journal:  Cancer Biol Ther       Date:  2015-09-29       Impact factor: 4.742

Review 7.  MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours.

Authors:  Michele Ghidini; Jens C Hahne; Melissa Frizziero; Gianluca Tomasello; Francesco Trevisani; Andrea Lampis; Rodolfo Passalacqua; Nicola Valeri
Journal:  Target Oncol       Date:  2018-08       Impact factor: 4.493

8.  Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab.

Authors:  Samantha Epistolio; Marco Cefalì; Paolo Spina; Francesca Molinari; Alessandra Movilia; Massimiliano Cergnul; Luca Mazzucchelli; Sara De Dosso; Milo Frattini; Piercarlo Saletti
Journal:  Oncotarget       Date:  2021-05-25

Review 9.  Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.

Authors:  Daniel V T Catenacci
Journal:  Mol Oncol       Date:  2014-10-18       Impact factor: 6.603

Review 10.  Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists.

Authors:  Jean-Baptiste Rey; Vincent Launay-Vacher; Christophe Tournigand
Journal:  Target Oncol       Date:  2014-09-12       Impact factor: 4.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.